RedHill Biopharma announces U.S. government funding for Opaganib development

RedHill Biopharma announced that opaganib has been awarded a further $1.7M in U.S. Government funding, via a Small Business Innovation Research grant to the company’s development partner, Apogee Biotechnology Corporation. This SBIR grant will support research to further the development of opaganib as a medical countermeasure for gastrointestinal acute radiation syndrome. This grant is in addition and complementary to the multimillion dollar-valued U.S. Government Radiation and Nuclear Countermeasures Program product pipeline development contract awarded to opaganib following its selection by the RNCP for ARS development.